TSHA logo

TAYSHA GENE THERAPIES INC

TSHANASDAQ
🏆 #2177 by market capEarnings Nov 10US Equity
$4.22▼ $0.01 (−0.24%)
Pre-market · at close
🔔
Track TSHA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.2%
7d▲ 6.4%
14d▲ 16.3%
30d▼ 13.5%
ytd▼ 23.1%
1y▼ 14.1%
🏦Market Cap
$1.37B
Small Cap
📈Revenue Growth (YoY)
17.3%
Healthy
📊Gross Margin
84.0%
High
💵FCF Margin
-2471.7%
Thin
⚖️P/S Ratio
249.9x
Expensive
Otter Score
48
Weak

Trading Snapshot

Day Range
$4.14 – $4.47
52-Week Range
$3.46 – $7.30
Volume (shares)
160,096
Avg Volume (shares)
—
Shares Outstanding
324.9M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
$10M
Last Q Revenue
—
P/E Ratio
-10.0
P/S Ratio
249.9x
EPS (TTM)
$-0.41
Dividend Yield
0.00%
Dilution (1yr)
+56.0%
TSHA logo

TAYSHA GENE THERAPIES INC

TSHA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$10M▲ +17.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$110M▲ +20.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$94M▲ +15.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
319.7M▲ +56.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$302M▲ +$226M YoY
StockOtter · stockotter.space

About TAYSHA GENE THERAPIES INC

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100

Analyst Ratings

ⓘ
Consensus
Buy
19 analysts
Strong Buy7
Buy11
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.